| Anthony Minke, NP | |
|
5225 23rd Ave S, Fargo, ND 58104-7927 | |
| (701) 799-9811 | |
| Not Available |
| Full Name | Anthony Minke |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 5225 23rd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265059547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R40649 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.
Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today that finds that 71 percent of Americans favor an increased investment in disease prevention and that disease prevention is one of the most popular components of health reform. Forty-four percent of Americans strongly favor investing more in prevention.
In a cross-sectional study from the 2004 and 2007 Australian National Drug Strategy Household (NDSH) surveys, respondents were questioned about their current and past drinking, the presence of formal diagnosis for specific diseases (heart disease, type 2 diabetes, hypertension, cancer, anxiety, depression) and self-perceived general health status. The sample sizes for the 2004 and 2007 NDSH surveys were 24,109 and 23,356, respectively.
› Verified 7 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.
Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today that finds that 71 percent of Americans favor an increased investment in disease prevention and that disease prevention is one of the most popular components of health reform. Forty-four percent of Americans strongly favor investing more in prevention.
In a cross-sectional study from the 2004 and 2007 Australian National Drug Strategy Household (NDSH) surveys, respondents were questioned about their current and past drinking, the presence of formal diagnosis for specific diseases (heart disease, type 2 diabetes, hypertension, cancer, anxiety, depression) and self-perceived general health status. The sample sizes for the 2004 and 2007 NDSH surveys were 24,109 and 23,356, respectively.
› Verified 7 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.
Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today that finds that 71 percent of Americans favor an increased investment in disease prevention and that disease prevention is one of the most popular components of health reform. Forty-four percent of Americans strongly favor investing more in prevention.
In a cross-sectional study from the 2004 and 2007 Australian National Drug Strategy Household (NDSH) surveys, respondents were questioned about their current and past drinking, the presence of formal diagnosis for specific diseases (heart disease, type 2 diabetes, hypertension, cancer, anxiety, depression) and self-perceived general health status. The sample sizes for the 2004 and 2007 NDSH surveys were 24,109 and 23,356, respectively.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Minke, NP 5225 23rd Ave S, Fargo, ND 58104-7927 Ph: (701) 417-2000 | Anthony Minke, NP 5225 23rd Ave S, Fargo, ND 58104-7927 Ph: (701) 799-9811 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.
Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today that finds that 71 percent of Americans favor an increased investment in disease prevention and that disease prevention is one of the most popular components of health reform. Forty-four percent of Americans strongly favor investing more in prevention.
In a cross-sectional study from the 2004 and 2007 Australian National Drug Strategy Household (NDSH) surveys, respondents were questioned about their current and past drinking, the presence of formal diagnosis for specific diseases (heart disease, type 2 diabetes, hypertension, cancer, anxiety, depression) and self-perceived general health status. The sample sizes for the 2004 and 2007 NDSH surveys were 24,109 and 23,356, respectively.
› Verified 7 days ago
Wendy M Moore, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 901 28th St S, Fargo, ND 58103 Phone: 701-404-1100 Fax: 701-540-6498 | |
Mrs. Kayla L. Nelson, DNP, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 301 Np Ave N, Fargo, ND 58102 Phone: 701-271-3344 | |
Kyrie Marie Severson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4622 40th Ave S, Suite A, Fargo, ND 58104 Phone: 701-364-2909 Fax: 701-364-9822 | |
Sadie Marie Nelson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Sanford Broadway Clinic, 801 North Broadway, Fargo, ND 58102 Phone: 701-234-2000 | |
Jessica Smolen, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 321 8th Ave N, Fargo, ND 58102 Phone: 701-234-2525 | |
Mr. Nicholas Henry Frederiksen, APRN,CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Erin Marie Wilmes Reiniger, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4671 38th St S, Fargo, ND 58104 Phone: 701-404-5100 Fax: 701-499-1166 |